Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition |
On May8, 2017, Portola Pharmaceuticals, Inc. issued a press
release announcing its financial results for the quarter ended
March31, 2017. The full text of the press release issued in
connection with the announcement is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein
by reference.
The information in
this Form 8-K and the Exhibit attached hereto shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
| Item9.01 | Financial Statements and Exhibits |
(d)
Exhibits
|
Number |
Description of Document |
|
| 99.1 |
Press release entitled Portola Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update dated May8, 2017. |
About Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Recent Trading Information
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) closed its last trading session down -0.93 at 37.31 with 599,339 shares trading hands.
